Zhejiang Tianyu Pharmaceutical Co Ltd: A Snapshot of Recent Performance and Operations
Zhejiang Tianyu Pharmaceutical Co., Ltd., a prominent player in the pharmaceutical intermediate and API sector, has recently been in the spotlight due to its performance on the Shenzhen Stock Exchange. As of May 29, 2025, the company’s close price stood at 22.67 CNY, with a 52-week high of 23.28 CNY recorded on the same day. The 52-week low was noted at 13.55 CNY on September 23, 2024. The company’s market capitalization is currently valued at 7,721,614,608 CNY, reflecting its significant presence in the health care sector.
Founded in 1993 and headquartered in Taizhou, China, Zhejiang Tianyu Pharmaceutical Co., Ltd. has established itself as a key player in the pharmaceutical industry. The company specializes in a range of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), focusing on cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic products. These specialties underscore the company’s commitment to addressing critical health issues through innovative pharmaceutical solutions.
Operating both domestically and internationally, Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in comprehensive activities that span research, development, manufacturing, and sales. This integrated approach allows the company to maintain a robust pipeline of products and ensures a steady presence in the competitive pharmaceutical market.
The company’s financial metrics, such as the price-to-earnings ratio of 77.3887, indicate investor confidence and the market’s valuation of its growth potential. As a publicly traded entity on the Shenzhen Stock Exchange, Zhejiang Tianyu Pharmaceutical Co., Ltd. continues to attract attention from investors and stakeholders interested in the health care sector’s dynamic landscape.
For more information about the company and its offerings, interested parties can visit their official website at www.tianyupharm.com .